U.S. Stock Market Midday Update

Iovance Biotherapeutics rose 7.63%, with increased trading volume. Based on recent important news:

1. On July 8, Iovance Biotherapeutics announced the resignation of Chief Financial Officer Jean-Marc Bellemin, alleviating market concerns about the company's future financial management, leading to a 7.63% increase in stock price.

2. On July 8, Bleichmar Fonti & Auld LLP filed a securities lawsuit against Iovance, impacting investor confidence, but failing to prevent the stock price from rising.

3. On July 7, Gross Law Firm issued a statement encouraging Iovance shareholders to participate in a class action lawsuit, with a positive market reaction.

Stocks with High Trading Volume in the Industry

ProKidney rose 24.66%, with increased trading volume. Based on recent important news:

1. On July 8, ProKidney announced positive results from its REGEN-007 trial, showing that Rilparencel significantly improved eGFR slope in chronic kidney disease patients, leading to a 24.66% increase in stock price.

2. On July 8, the company confirmed no serious adverse events, enhancing market confidence in its safety.

3. On July 8, trial results drove trading volume to 39.8 million shares, far exceeding the average level.

Calidi Biotherapeutics rose 300.33%, with a trading volume of $350 million. Based on recent key news:

1. On July 8, Calidi Biotherapeutics announced it was mentioned in an editorial published by NetworkNewsWire, which attracted significant market attention, resulting in a substantial 300.33% increase in stock price.

AbbVie rose 0.15%, with increased trading volume. Based on recent important news:

1. On July 9, analysts rated AbbVie as a moderate buy, not included in the top recommended stocks list, affecting market confidence and causing stock price fluctuations.

2. On July 8, breakthroughs in CAR-T cell therapy in the field of autoimmune diseases may boost market expectations for AbbVie's related products.

3. On July 7, changes in the investment structure of the innovative drug industry, with institutions increasing their positions, drove the stock price up.

Stocks with High Market Capitalization in the Industry

AbbVie rose 0.15%, with increased trading volume. Based on recent important news:

1. On July 9, analysts believed AbbVie's investment value was lower than that of five other stocks, leading to insufficient market confidence and stock price fluctuations.

2. On July 9, changes in the investment structure of the innovative drug industry, with institutions increasing their positions in innovative drugs, drove the stock price up.

3. On July 7, breakthroughs in CAR-T cell therapy in the field of autoimmune diseases raised market expectations for AbbVie